Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC (CONTERNO)
A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer
Sponsor: Checkpoint Therapeutics, Inc.
Terminated
Regional political conflict
Listed as NCT04786964, this PHASE3 trial focuses on Metastatic Non-squamous Non Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Checkpoint Therapeutics, Inc., it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — May 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 5 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Checkpoint Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arkhangelsk, Russia , Chelyabinsk, Russia , Chiang Mai, Thailand , Kaliningrad, Russia , Kazan', Russia , Kota Bharu, Malaysia , Kursk, Russia , Kuzmolovskiy, Russia , Lima, Peru , Moscow, Russia and 12 more locations